T
Tahar van der Straaten
Researcher at Leiden University Medical Center
Publications - 59
Citations - 1832
Tahar van der Straaten is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: DNA repair & Single-nucleotide polymorphism. The author has an hindex of 23, co-authored 58 publications receiving 1686 citations. Previous affiliations of Tahar van der Straaten include Loyola University Medical Center & Leiden University.
Papers
More filters
Journal ArticleDOI
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
Nielka P. van Erp,Karel Eechoute,Astrid A.M. van der Veldt,John B. A. G. Haanen,An K.L. Reyners,Ron H.J. Mathijssen,Epie Boven,Tahar van der Straaten,Renee Baak-Pablo,Judith A.M. Wessels,Henk-Jan Guchelaar,Hans Gelderblom +11 more
TL;DR: This exploratory study suggests that polymorphisms in specific genes encoding for metabolizing enzymes, efflux transporters, and drug targets are associated with sunitinib-related toxicities.
Journal ArticleDOI
Almost the entire 5′ non-translated region of hepatitis C virus is required for cap-independent translation
Rene Rijnbrand,Peter J. Bredenbeek,Tahar van der Straaten,Linda E. Whetter,Genevieve Inchauspe,Stanley M. Lemon,Willy J. M. Spaan +6 more
TL;DR: It is demonstrated that HCV 5′UTR driven translation is stimulated by poliovirus 2Apro co‐expression, and each of the predicted hairpins is found to be essential for cap‐independent translation.
Journal ArticleDOI
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Rogier R. Press,Bart A. Ploeger,Jan den Hartigh,Tahar van der Straaten,Johannes van Pelt,Meindert Danhof,Johan W. de Fijter,Henk-Jan Guchelaar +7 more
TL;DR: An integrated analysis shows that adult renal transplant recipients with the CYP3A5*1/*3 genotype require a 1.5 times higher, fixed, starting dose compared with CYP5*3/*3 to reach the predefined target exposure early after transplantation.
Journal ArticleDOI
Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis.
Eric L. Kaijzel,Michiel V van Krugten,Brigitta M. N. Brinkman,Tom W J Huizinga,Tahar van der Straaten,J. Mieke W. Hazes,H. W. Loems Ziegler-Heitbrock,Sergei A. Nedospasov,Sergei A. Nedospasov,Ferdinand C. Breedveld,Cornelis L. Verweij +10 more
TL;DR: In vitro transfection assays indicate that T NF-238A by itself or in combination with TNF-376A is not likely to be of direct functional relevance for transcriptional activation, and these polymorphisms may serve as markers for additional polymorphisms in the TNF/LT locus or neighboring genes that may influence disease severity.
Journal ArticleDOI
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
Jan Pander,Moniek Heusinkveld,Tahar van der Straaten,Ekaterina S. Jordanova,Renee Baak-Pablo,Hans Gelderblom,Hans Morreau,Sjoerd H. van der Burg,Henk-Jan Guchelaar,Thorbald van Hall +9 more
TL;DR: It is suggested that tumor-promoting M2 macrophages are activated by the therapeutic mAb cetuximab in the local tumor microenvironment and argued that this immune mechanism should be taken into account for the application of therapeutic antibodies.